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Abstract
Finding safe and effective treatments for chronic hepatitis C virus (HCV) infection in the
elderly is of clinical interest given the comorbidities and associated polypharmacy in this
population. However, the number of patients older than age 65 years enrolled into clinical tri-
als of anti-HCV medications generally have been limited and thus reaching meaningful con-
clusions for this demographic has been difficult. Glecaprevir/pibrentasvir is a once-daily, all-
oral, ribavirin-free, pangenotypic direct-acting antiviral (DAA) combination therapy that has
demonstrated high sustained virologic response rates at post-treatment week 12 (SVR12)
and a favorable safety profile in patients with chronic HCV infection. This analysis evaluated
the safety and efficacy of glecaprevir/pibrentasvir in patients aged�65 years. Data were
pooled for treatment-naïve and -experienced patients with chronic HCV genotype (GT) 1–6
infections who received glecaprevir/pibrentasvir for 8, 12, or 16 weeks in 9 Phase 2 and 3 tri-
als. SVR12 and adverse events (AEs) were evaluated for patients aged�65 versus <65
years. Of the 2369 patients enrolled, 328 (14%) were aged�65 years. Among patients
aged�65 years, 42% and 34% had GT1 and GT2, respectively; 40% were treatment-expe-
rienced and 20% had compensated cirrhosis. Glecaprevir/pibrentasvir treatment resulted in
SVR12 rates of 97.9% (95% CI, 96.3–99.4; n/N = 321/328) for patients aged�65 years and
97.3% (95% CI, 96.6–98.0; n/N = 1986/2041) for patients aged <65 years. The rates were
not significantly different between the two age groups (P = 0.555). DAA-related AEs leading
to treatment discontinuation, or serious AEs were similarly rare (<0.5%) for patients�65
and <65 years old. Glecaprevir/pibrentasvir is an efficacious and well-tolerated treatment
option for patients aged�65 years with chronic HCV infection.
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Introduction
The age of the global population of patients with chronic hepatitis C virus (HCV) infection is
gradually increasing, in particular in the United States, Japan, and Italy [1–5]. As patients
enter older age, it is important to understand the impact of age on the safety and efficacy of
current HCV antiviral therapies. However, patients of advanced age have typically been
under-represented in clinical trials of anti-HCV therapies and robust data are lacking for this
patient group [6, 7].
Elderly patients historically have been considered difficult to treat [6]. Older age is associ-
ated with a greater prevalence of advanced fibrosis, more rapid fibrosis progression and cirrho-
sis, and a greater risk of liver cancer than younger age [6, 7]. Comorbidities that require the
frequent use of concomitant medications are more common in elderly patients, compared
with younger patients, and therefore there is a potential risk of exposure to drug–drug interac-
tions. [8]. New, all-oral direct-acting antivirals (DAAs) have a much better tolerability profile
compared with previous interferon (IFN)-based regimens [7]. Furthermore, findings in real-
world studies support that DAAs have high efficacy, safety, and tolerability in elderly patients
[9–12]. However, elderly patients are frequently excluded from clinical trials of DAA efficacy
and safety [13].
Glecaprevir/pibrentasvir is a once-daily, all-oral, ribavirin (RBV)-free, pangenotypic, DAA
combination therapy that has shown high rates of sustained virologic response at post-treat-
ment week 12 (SVR12) and a favorable safety profile in patients with chronic HCV infection,
including patients with compensated cirrhosis, prior treatment failures to IFN-based and
DAA-containing regimens, severe kidney impairment including dialysis, patients who are post
liver or kidney transplant [14], or those with human immunodeficiency virus (HIV) coinfec-
tion [15–23]. To evaluate the safety and efficacy of glecaprevir/pibrentasvir in elderly patients,
an analysis of integrated data from patients aged 65 years or older enrolled in glecaprevir/
pibrentasvir’s registrational clinical trial program was conducted. There was no upper age
limit for enrollment into the program.
Methods
This is an analysis using data integrated from patients who received glecaprevir 300 mg and
pibrentasvir 120 mg enrolled in registrational clinical trials of glecaprevir/pibrentasvir for the
treatment of chronic HCV infections. These comprise 9 Phase 2 and 3, multicenter, clinical
studies: MAGELLAN-1 (NCT02446717) [20, 22], SURVEYOR-I and -II (NCT02243280 and
NCT02243293) [15, 18, 19, 21], ENDURANCE-1 (NCT02604017) [23], ENDURANCE-2
(NCT02640482) [15], ENDURANCE-3 (NCT02640157) [23], ENDURANCE-4
(NCT02636595) [15], EXPEDITION-1 (NCT02642432) [16], and EXPEDITION-4
(NCT02651194) [17].
The protocols, designed and sponsored by AbbVie Inc., Chicago, IL, for the original trials
were approved by the independent ethics committee or institutional review board for each
trial center. The trials were conducted in accordance with the Good Clinical Practice Guide-
lines and the ethical principles of the Declaration of Helsinki, and all patients provided written
informed consent. All authors had access to trial data and participated in the writing, review,
and approval of the final manuscript. All trial data were fully anonymized prior to access by
the authors. For trials included in this analysis, Dr Foster and Dr Asselah were Principal Inves-
tigators; Dr Armen Asatryan and Dr Neddie Zadeikis were Lead Medical Directors; Dr Yang
Lei was the Clinical Statistician; and Dr Sarah Kopecky-Bromberg was the Clinical Scientist.
Dr Roger Trinh and Dr Federico Mensa designed the protocols and provided study oversight
for these trials as well as the glecaprevir/pibrentasvir clinical program.
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Patients
The trials enrolled patients aged�18 years with no upper age limit with chronic HCV geno-
type (GT) 1–6 infections (HCV RNA�1000 IU/mL). HCV GT at baseline was determined
by the central laboratory; for efficacy analyses, HCV GT was determined by phylogenetic
analysis (or Sanger sequencing if phylogenetic analysis was not available). Patients were
either non-cirrhotic or had compensated cirrhosis. Absence of cirrhosis was confirmed by
liver biopsy, transient elastography (FibroScan [Echosens, Paris, France] <12.5 kPa), or
serum markers (FibroTest [BioPredictive, Paris, France]�0.48 and aminotransferase-to-
platelet ratio index [APRI] <1). Presence of cirrhosis was documented by a liver biopsy with
a METAVIR (or equivalent) fibrosis score of 3 or Ishak fibrosis score >4; FibroTest score
�0.75 with APRI >2, or FibroScan�14.6 kPa; and patients must have had a Child–Pugh
score of �6 at screening and no current or past evidence of Child–Pugh B or C classification
or clinical history of liver decompensation. Patients with indeterminate FibroScan were
required to have liver biopsy, and patients with indeterminate FibroTest or conflicting
FibroTest and APRI scores were required to have transient elastography or liver biopsy to
determine cirrhosis status. The elderly population for this analysis was defined as patients
aged 65 years or older.
Patients were HCV treatment-naïve or had failed previous HCV therapy with IFN ± RBV,
pegylated IFN ± RBV, or sofosbuvir + RBV ± pegylated IFN. Patients in the MAGELLAN-1
trial had completed treatment with a DAA-containing regimen (NS5A inhibitor with or with-
out protease inhibitor) with an outcome of on-treatment failure or post-treatment relapse [20,
22]. Patients coinfected with hepatitis B virus, or with more than one HCV GT were excluded.
ENDURANCE-1 included patients with HIV coinfection [23] and EXPEDITION-4 was a ded-
icated study conducted in patients with severe renal impairment, including those undergoing
dialysis [17].
Treatments
All patients received glecaprevir 300 mg and pibrentasvir 120 mg once daily (dosed as separate
medications or as 3 coformulated 100 mg/40 mg oral tablets taken once daily with food) for 8,
12, or 16 weeks.
Outcomes and statistical analyses
The primary endpoint for each trial was the percentage of patients who achieved SVR12 (HCV
RNA <15 IU/mL) in the intention-to-treat (ITT) population, defined as all randomized
patients who received at least 1 dose of study drug. Both the COBAS TaqMan HCV Test (v2.0)
and COBAS AmpliPrep/COBAS TaqMan HCV Test (v2.0) kits (Roche Molecular Diagnostics)
were used across the studies in this analysis to determine HCV RNA concentrations. Efficacy
was analyzed using data pooled for patients aged�65 years or<65 years. Two-sided 95% con-
fidence intervals (CIs) for SVR12 rates were calculated using the normal approximation to the
binomial distribution. Backward imputation was used to impute missing SVR12 data, where
applicable. Otherwise, patients with missing data were counted as treatment failures. The dif-
ference in the overall SVR12 rates between the two age groups was analyzed using a two-tailed
Fisher’s exact test. SVR12 was also analyzed for the modified ITT (mITT) population, defined
as the ITT population excluding patients who did not achieve SVR12 for reasons other than
virologic failure. Patients who had low compliance but stayed in the study were not excluded
in this mITT. Adverse events (AEs; Medical Dictionary for Regulatory Activities version 19.0)
and laboratory abnormalities were monitored and recorded throughout the studies and are
summarized using descriptive statistics. Because most of the clinical trials excluded patients
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with an estimated creatinine clearance of<50 mL/minute, safety outcomes were evaluated
separately for patients with and without severe renal impairment as it would be expected that
patients with severe renal impairment would have a different safety profile from those without
severe renal impairment.
Results
Patients
A total of 2369 patients were included in this analysis: 328 patients aged�65 years, 2041
patients aged <65 years, and 47 patients aged �75 years (Table 1). Most elderly patients
were white (68%), HCV treatment-naïve (60%), and did not have cirrhosis (80%). The
majority of elderly patients received either 8 weeks (29%) or 12 weeks (65%) of treatment
with glecaprevir/pibrentasvir. Compared with non-elderly patients, patients in the elderly
cohort tended to have a greater frequency of HCV GT2 (i.e., 34% vs 18%) and HCV GT5
infections (i.e. 4% vs 1%), and less frequency of HCV GT3 infections (i.e., 11% vs 30%;
Table 1). As expected, prevalence of some comorbidities tended to be greater for elderly
patients than for younger patients, such as cirrhosis (20% vs 12%), diabetes (17% vs 7%),
hypertension (54% vs 23%), cardiovascular disease (62% vs 28%), and severe renal
impairment (estimated glomerular filtration rate <30 mL/min/1.73 m2; 9% vs 4%). Non-
elderly patients reported a greater frequency of bipolar disorder or depression compared
with elderly patients (22% vs 16%). Elderly patients were also more likely to be receiving
some concomitant medications corresponding to the increased prevalence of reported
comorbidities in this population, including antihypertensive (45% vs 18%), diuretic (15% vs
6%), and lipid-lowering medications (15% vs 7%; Table 2; see S1 Table for concomitant med-
ications in patients with severe renal impairment). The percentage of patients receiving ant-
acids and proton pump inhibitors, and antidepressants, were similar between elderly and
non-elderly patients (19% vs 15% and 14% vs 16%, respectively). Overall rates of compliance
were similar between the two age groups (88% vs 90%; Table 1). For patients who were
receiving 4 or more concomitant medications in addition to glecaprevir/pibrentasvir, 84% of
elderly patients (n/N = 163/195) were compliant with the study drug versus 89% of non-
elderly patients (n/N = 708/797; see S2 Table).
Efficacy
The overall SVR12 rate for the ITT population was 97.4% (95% CI, 96.7–98.0; n/N = 2307/
2369). Elderly patients achieved an SVR12 rate of 97.9% (95% CI, 96.3–99.4; n/N = 321/328)
and the non-elderly patients achieved an SVR12 rate of 97.3% (95% CI, 96.6–98.0; n/N = 1986/
2041) (Fig 1A). The rates were not significantly different between the two age groups
(P = 0.555). The overall SVR12 rate for the mITT population was 98.6% (95% CI, 98.1–99.1; n/
N = 2307/2340): 99.4% (95% CI, 98.5–100; n/N = 321/323) for elderly patients and 98.5% (95%
CI, 97.9–99.0; n/N = 1986/2017) for non-elderly patients.
Overall SVR12 rates were generally unaffected by HCV GT, fibrosis stage, treatment dura-
tion and compliance (Fig 1A–1D; S3 Table). SVR12 rates were similar for elderly and non-
elderly patients across HCV GTs, fibrosis stages, and glecaprevir/pibrentasvir treatment dura-
tions (Fig 1A–1C; S3 Table). SVR12 rates also appeared to be comparable between elderly and
non-elderly patients grouped by treatment compliance status (Fig 1D; S3 Table).
Seven elderly patients (2%) did not achieve SVR12 (mean [standard deviation] age, 67
[±1.7] years). Of these, 3 patients discontinued treatment, 2 patients had on-treatment viro-
logic failure, and 2 patients had missing SVR12 data.
Glecaprevir/Pibrentasvir for HCV infection in elderly patients
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Table 1. Baseline demographics and clinical characteristics.
Characteristics Patients Aged�65 Years
(n = 328)
Patients Aged <65 Years
(n = 2041)
Total (N = 2369) P-valuef
Female, n (%) 149 (45) 902 (44) 1051 (44) 0.677
Race, n (%)
White 223 (68) 1675 (82) 1898 (80) <0.001
Black 33 (10) 116 (6) 149 (6) 0.002
Asian 68 (21) 204 (10) 272 (11) <0.001
Othera 4 (1) 46 (2) 50 (2)
Hispanic or Latino ethnicity, n (%) 31 (9) 180 (9) 211 (9) 0.709
Age, mean ± SD (range), years 69.3 ± 4.3 (65–88) 49.8 ± 10.4 (19–64) 52.5 ± 11.8 (19–
88)
<0.001
�75 years, n (%) 47 (14) – 47 (2) <0.001
Body mass index, mean (SD), kg/m2 26.5 (4.9) 26.7 (5.1) 26.7 (5.1) 0.476
�30 kg/m2, n (%) 66 (20) 436 (21) 502 (21) 0.610
HCV genotype, n (%)
GT1 139 (42) 848 (42) 987 (42) 0.777
GT2 111 (34) 366 (18) 477 (20) <0.001
GT3 37 (11) 606 (30) 643 (27) <0.001
GT4 24 (7) 158 (8) 182 (8) 0.789
GT5 12 (4) 20 (1) 32 (1) <0.001
GT6 5 (2) 43 (2) 48 (2) 0.487
IL28B genotype, n (%)b
CC 113 (35) 653 (32) 766 (32) 0.361
CT 155 (47) 1069 (52) 1224 (52) 0.093
TT 59 (18) 318 (16) 377 (16) 0.260
HCV RNA, mean (SD), log10 IU/mL 6.1 (0.9) 6.1 (0.8) 6.1 (0.8) 0.066
HCV RNA, n (%)
�1 million IU/mL 200 (61) 1207 (59) 1407 (59) 0.529
�6 million IU/mL 60 (18) 457 (22) 517 (22) 0.095
Treatment history, n (%)
Treatment-naïve 198 (60) 1442 (71) 1640 (69) <0.001
Treatment-experienced 130 (40) 599 (29) 729 (31) <0.001
IFN/pegIFN ± RBV ± sofosbuvir 115 (35) 501 (25) 616 (26) <0.001
NS5A ± NS3/4A protease inhibitor 15 (5) 98 (5) 113 (5) 0.857
Fibrosis stage, n (%)c
F0–F1 188 (57) 1463 (72) 1651 (70) <0.001
F2 33 (10) 132 (6) 165 (7) 0.018
F3 45 (14) 200 (10) 245 (10) 0.032
F4 62 (19) 241 (12) 303 (13) <0.001
Cirrhosis status, n (%)
Compensated cirrhosis 64 (20) 244 (12) 308 (13) <0.001
No cirrhosis 264 (80) 1797 (88) 2061 (87) <0.001
Estimated glomerular filtration rate <30 mL/min/1.73 m2, n
(%)d
28 (9) 75 (4) 103 (5) <0.001
Diabetes, n (%) 57 (17) 147 (7) 204 (9) <0.001
Bipolar disorder or depression, n (%) 52 (16) 456 (22) 508 (21) 0.008
Hypertension, n (%) 177 (54) 478 (23) 655 (28) <0.001
Cardiovascular disease, n (%) 204 (62) 572 (28) 776 (33) <0.001
Glecaprevir/pibrentasvir treatment duration, n (%)
(Continued)
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Safety
The overall safety profile of elderly patients without severe renal impairment was similar to
that of non-elderly patients (Table 3). A total of 63% of elderly patients without severe renal
impairment experienced AEs, most of which were Grade 1 (mild) to Grade 2 (moderate) in
severity. The most common AEs experienced by elderly patients without severe renal
impairment were headache (12%) and fatigue (11%). There were some statistically significant
differences between elderly and non-elderly patients in the frequency of individual AEs and
the incidence of serious AEs; however, the small sample sizes in these subsets of patients make
it difficult to achieve clinically meaningful conclusions. AEs were considered to be related to
glecaprevir/pibrentasvir treatment in 36% of elderly patients. Four percent of elderly patients
without severe renal impairment experienced serious AEs (SAEs), none of which were consid-
ered to be related to glecaprevir/pibrentasvir treatment. None of the elderly patients discontin-
ued treatment because of AEs related to glecaprevir/pibrentasvir treatment. Less than 1% of
Table 1. (Continued)
Characteristics Patients Aged�65 Years
(n = 328)
Patients Aged <65 Years
(n = 2041)
Total (N = 2369) P-valuef
8 weeks 94 (29) 756 (37) 850 (36) 0.003
12 weeks 214 (65) 1185 (58) 1399 (59) 0.014
16 weeks 20 (6) 100 (5) 120 (5) 0.358
Treatment compliancee, n (%)
Compliant 289 (88) 1832 (90) 2121 (90) 0.365
Non-compliant 39 (12) 209 (10) 248 (10) 0.365
GT, genotype; HCV, hepatitis C virus; IL28B, interleukin 28B; PegIFN, pegylated interferon; RBV, ribavirin; RNA, ribonucleic acid; SD, standard deviation.
aOther category includes American Indian or Alaska native, Native Hawaiian or other Pacific Islander, multiple races, and missing data.
bData missing for 1 patient each from the elderly and non-elderly cohorts.
cData missing for 5 patients in the non-elderly cohort.
dData missing for 1 patient in the non-elderly cohort; overall percentage calculated using a total population (N) of 2238.
eCompliant was defined as 80%–120% of expected glecaprevir/pibrentasvir intake.
fP-values were calculated for the elderly and non-elderly comparison using a Chi-square test for categorical data and one-way ANOVA for continuous data; P-values for
treatment compliance are based on 2 by 2 contingency table.
https://doi.org/10.1371/journal.pone.0208506.t001
Table 2. Concomitant medications.
Medication, n (%) Patients Aged�65 Years (n = 328) Patients Aged <65 Years (n = 2041) Total (N = 2369) P-valuec
Any 302 (92) 1638 (80) 1940 (82) <0.001
Acid-reducing agentsa 63 (19) 299 (15) 362 (15) 0.332
Antidepressants 46 (14) 317 (16) 363 (15) 0.482
Antihypertensivesb 146 (45) 364 (18) 510 (22) <0.001
Diuretics 50 (15) 131 (6) 181 (8) <0.001
Antipsychotics 10 (3) 88 (4) 98 (4) 0.286
Diabetes medications (including insulin) 50 (15) 145 (7) 195 (8) <0.001
Lipid-lowering drugs 49 (15) 134 (7) 183 (8) <0.001
aIncludes antacids and proton pump inhibitors.
bIncludes angiotensin II antagonists, beta-blocking drugs, calcium channel blockers, potassium-sparing drugs, and angiotensin-converting enzyme inhibitors (patients
may have been receiving more than 1 of these medications and therefore may have been counted more than once).
cP-values were calculated using a Chi-square test.
https://doi.org/10.1371/journal.pone.0208506.t002
Glecaprevir/Pibrentasvir for HCV infection in elderly patients
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Fig 1. Sustained virologic response at post-treatment week 12 by A) hepatitis C virus genotype; B) fibrosis stage; C)
glecaprevir/pibrentasvir treatment duration; and D) glecaprevir/pibrentasvir treatment compliancea (ITT analyses).
Glecaprevir/Pibrentasvir for HCV infection in elderly patients
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patients without severe renal impairment died: 2 patients in the elderly cohort and 4 in the
non-elderly cohort. None of the deaths were considered to be related to glecaprevir/pibrentas-
vir treatment; MedDRA-coded preferred terms listed for cause of death were: metastatic
hepatic cancer, pneumonia, death, accidental overdose, cerebral hemorrhage,
adenocarcinoma.
For patients with severe renal impairment, 79% of elderly and 68% of non-elderly patients
experienced AEs (Table 4). The most common AE experienced by elderly patients with severe
renal impairment was pruritus (32%) followed by fatigue, nausea, asthenia, and decreased
appetite (18% each), which are consistent with the underlying renal failure. The AEs among
these patients were considered to be treatment related in 57% of elderly and 46% of non-
elderly patients. A total of 39% of elderly patients experienced AEs of Grade�3 severity com-
pared with 18% of non-elderly patients. Grade�3 AEs were considered to be treatment related
in 7% and 4% of elderly and non-elderly patients with severe renal impairment, respectively. A
total of 39% of elderly patients with severe renal impairment experienced SAEs, of which none
were considered to be treatment related. One patient with severe renal impairment discontin-
ued treatment because of AEs that were considered to be related to glecaprevir/pibrentasvir
treatment. One non-elderly patient with severe renal impairment died; the death was not con-
sidered related to glecaprevir/pibrentasvir treatment.
Few elderly patients experienced clinically significant laboratory abnormalities (Table 5).
Overall, <1% (2 patients) had Grade 3 elevations in total bilirubin levels, <1% (1 patient) had
Grade 3 decreases in hemoglobin levels, and<1% (1 patient) had Grade 3 decreases in platelet
levels. Post-baseline laboratory abnormalities were similarly infrequent (1%) in non-elderly
patients.
aCompliant was defined as 80%–120% of expected glecaprevir/pibrentasvir intake. F, fibrosis stage; GT, genotype; ITT,
intention-to-treat; SVR12, sustained virologic response at post-treatment week 12; VF, virologic failure.
https://doi.org/10.1371/journal.pone.0208506.g001
Table 3. Summary of adverse events for patients without severe renal impairmenta.
Event, n (%) Patients Aged�65 Years (n = 300) Patients Aged <65 Years (n = 1965) P-valueb
Any AE 189 (63) 1340 (68) 0.074
AEs experienced by�10% of patients
Headache 36 (12) 374 (19) 0.003
Fatigue 32 (11) 298 (15) 0.04
Nausea 18 (6) 190 (10) 0.04
Any DAA-related AE 107 (36) 822 (42) 0.043
Any AE with Grade 3 severity or greater 13 (4) 52 (3) 0.103
Any DAA-related AE with Grade 3 severity or greater 0 4 (<1) 0.434
Any serious AE 13 (4) 35 (2) 0.004
Any DAA-related serious AE 0 1 (<1) 0.696
Any AE leading to treatment discontinuation 2 (<1) 6 (<1) 0.326
Any DAA-related AE leading to treatment discontinuation 0 3 (<1) 0.498
Fatal AEs 1 (<1) 1 (<1) 0.125
Deaths 2 (<1) 4 (<1) 0.146
AE, adverse event; DAA, direct-acting antiviral.
aEstimated glomerular filtration rate�30 mL/min/1.73 m2.
bP-values were calculated for the elderly and non-elderly comparison using a Chi-square test.
https://doi.org/10.1371/journal.pone.0208506.t003
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Discussion
This retrospective analysis of pooled data from 9 Phase 2 and 3 clinical trials was conducted to
assess the safety and efficacy of combination glecaprevir/pibrentasvir in elderly patients (aged
65 years or older). The results of this analysis indicate that once-daily glecaprevir/pibrentasvir
for 8, 12, or 16 weeks is a safe, well-tolerated, and highly efficacious treatment for chronic
HCV infection in elderly patients. The efficacy of glecaprevir/pibrentasvir was not significantly
Table 4. Summary of adverse events for patients with severe renal impairmenta.
Event, n (%) Patients Aged�65 Years (n = 28) Patients Aged <65 Years (n = 76) P-valueb
Any AE 22 (79) 52 (68) 0.311
AEs experienced by�10% of patientsc
Fatigue 5 (18) 10 (13)
Nausea 5 (18) 7 (9)
Diarrhea 4 (14) 6 (8)
Pruritus 9 (32) 12 (16)
Asthenia 5 (18) 5 (7)
Decreased appetite 5 (18) 4 (5)
Abdominal pain 3 (11) 1 (1)
Any DAA-related AE 16 (57) 35 (46) 0.316
Any AE with Grade 3 severity or greater 11 (39) 14 (18) 0.027
Any DAA-related AE with Grade 3 severity or greater 2 (7) 3 (4) 0.499
Any serious AE 11 (39) 14 (18) 0.027
Any DAA-related serious AE 0 0
Any AE leading to treatment discontinuation 2 (7) 2 (3) 0.289
Any DAA-related AE leading to treatment discontinuation 1 (4) 1 (1) 0.458
Fatal AEs 0 1 (1) 0.542
Deaths 0 1 (1) 0.542
AE, adverse event; DAA, direct-acting antiviral.
aEstimated glomerular filtration rate <30 mL/min/1.73 m2.
bP-values were calculated for the elderly and non-elderly comparison using a Chi-square test.
cP-values not calculated due to small sample size (<10) in either group.
https://doi.org/10.1371/journal.pone.0208506.t004
Table 5. Summary of post-baseline laboratory abnormalities.
Event, n/N (%) Patients Aged�65 Years Patients Aged <65 Years
Alanine aminotransferase
Grade 3 0 2/2039 (<1)a,b
Grade 4 0 0
Total bilirubin
Grade 3 2/328 (<1) 7/2039 (<1)b
Grade 4 0 0
aThe laboratory results were not associated with drug-induced liver injury, but were instead consistent with
fluctuations in alanine aminotransferase during the first 2 weeks of treatment or were due to other etiologies, such as
gallstones.
bOne patient with concurrent Grade 3 alanine aminotransferase and total bilirubin changes, which were attributable
to gallstones.
https://doi.org/10.1371/journal.pone.0208506.t005
Glecaprevir/Pibrentasvir for HCV infection in elderly patients
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impacted by HCV GT, fibrosis stage, treatment duration, or compliance, and was similar to
the efficacy observed in younger patients in these trials.
Glecaprevir/pibrentasvir was generally well tolerated by the elderly patients. Most AEs were
Grade 1 (mild) to Grade 2 (moderate) in severity, no SAEs were considered to be related to
treatment, and treatment discontinuations assessed as related to glecaprevir/pibrentasvir were
rare (<1%). Elderly patients with severe renal impairment tended to have a greater incidence
of some types of AEs; however, most AEs were considered unrelated to treatment with gleca-
previr/pibrentasvir, and the greater incidence of AEs experienced by this subgroup of patients
is expected given the severe renal impairment and the associated comorbidities [24, 25]. For
patients without severe renal impairment, the safety profiles of older and younger patients
were comparable.
The findings of this analysis add to the existing results obtained from previous studies of
DAAs for the treatment of chronic HCV infection in elderly patients. In a retrospective analy-
sis of pooled data from 4 Phase 3 clinical trials, ledipasvir/sofosbuvir with and without RBV
for 8, 12, or 24 weeks resulted in high efficacy for patients with chronic HCV GT1 infections
aged�65 years (SVR12 rate, 98% [95% CI, 95–99]; n = 264) and for patients aged<65 years
(SVR12 rate, 97% [95% CI, 96–98]; n = 2029) [13]. Although elderly patients had a greater
prevalence of cirrhosis at baseline, the efficacy of ledipasvir/sofosbuvir was not impacted,
which is consistent with our results [13].
Data accumulating from real-world clinical practice also support the high efficacy and
safety of all-oral DAAs reported in clinical trials. Elderly patients aged�65 years in Italy with
chronic HCV GT1–4 infections and advanced fibrosis or cirrhosis who received a variety of
sofosbuvir- and ombitasvir/paritaprevir/ritonavir-containing regimens, achieved an SVR12
rate of 94.7% (n = 282) versus 90.5% for patients aged<65 years (n = 274) [9]. SAEs were
uncommon (5%) and treatment discontinuations were rare (2%) in elderly patients compared
with younger patients, despite a greater prevalence of liver cancer history, more severe liver
disease, and presence of comorbidities such as arterial hypertension and renal disease [9]. In
the large real-world Spanish National Registry (Hepa-C) of>1200 patients aged�65 years
with chronic HCV GT1–5 infections treated with all-oral DAA regimens (mostly ledipasvir/
sofosbuvir-, simeprevir/sofosbuvir-, and ombitasvir/paritaprevir/ritonavir-containing regi-
mens), the SVR12 rate was 94% [10]. Likewise, in a real-world analysis of>17,000 patients in
the US Veterans Affairs Healthcare System (>4500 patients aged�65 years) with GT1–4
infections treated with ledipasvir/sofosbuvir- and ombitasvir/paritaprevir/ritonavir-contain-
ing regimens, advanced age was found to be not significantly associated with the likelihood of
achieving SVR12 [12].
In addition to clinical trials and real-world efficacy and safety studies of DAAs, emerging
data suggest that successful antiviral treatment in elderly patients can improve life expectancy
and health-related quality of life [26, 27]. These data suggest that the benefits of treating
chronic HCV infection in elderly patients may go beyond the elimination of HCV and HCV
infection-related comorbidities.
A key strength of this pooled analysis is that it included data from 9 Phase 2 and 3 well-
defined clinical trials with all available clinical and biological data, to assess the safety and effi-
cacy of combination glecaprevir/pibrentasvir in elderly patients (aged 65 years or older). The
results of this analysis indicate that once-daily glecaprevir/pibrentasvir for 8, 12, or 16 weeks is
a well-tolerated and highly efficacious treatment for chronic HCV infection in elderly patients.
Furthermore, eligibility criteria for the trials in this analysis specified no upper age limit for
inclusion; therefore, the study population represents a broad group of elderly patients. Limita-
tions include that this meta-analysis was post hoc. The clinical trials included in this analysis
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were not designed or statistically powered to compare specifically the efficacy and safety of gle-
caprevir/pibrentasvir in the elderly versus non-elderly patients.
In conclusion, glecaprevir/pibrentasvir is efficacious and well tolerated for the treatment of
chronic HCV infections in elderly patients. These findings add to the growing body of clinical
trial and real-world data supporting that age should not be a barrier to the initiation and suc-
cessful treatment of chronic HCV infection.
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